For the Inventor, By the Inventor

Enter assignee name

Buckinghamshire, United Kingdom

Respivert Limited

Calculating rank

USPTO Granted Patents = 63

% Expired Patents = 36.5

EPO Patents = 31

Forward Citations = 642

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

John King-Underwood (38 out of 39 patents)

Stuart Thomas Onions (37 out of 67 patents)

Kazuhiro Ito (27 out of 49 patents)

4. Peter John Murray (23 out of 38 patents)

5. Catherine Elisabeth Charron (21 out of 21 patents)

6. Alistair Ian Longshaw (18 out of 20 patents)

7. Jonathan Gareth Williams (17 out of 18 patents)

8. Matthew Colin Thor Fyfe (15 out of 23 patents)

9. Peter Strong (11 out of 38 patents)

10. William Garth Rapeport (11 out of 11 patents)

11. Stephen Thom (11 out of 60 patents)

12. Euan Alexander Fraser Fordyce (9 out of 20 patents)

13. George Hardy (8 out of 8 patents)

14. Alex Herman Copmans (8 out of 14 patents)

15. Jennifer Diane Venable (8 out of 52 patents)

Core Competencies:

Kinase Inhibitors

P38 MAP Kinase

Phosphoinositide 3-Kinase

Indole Derivatives

Pyrazolyl-Ureas

Respiratory Formulations

Fibrotic Diseases

Protein Kinase Inhibitors

Quinazolin Derivatives

Urea Derivatives

Pyrazole Derivatives

63 patents: Sort by Forward Citations

1. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

2. 11208381 - Indole derivatives and their use as protein kinase inhibitors (2021-12-28),

3. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

4. 11046672 - Indolinones compounds and their use in the treatment of fibrotic diseases (2021-06-29),

5. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

6. 10813932 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2020-10-27),

7. 10738032 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors (2020-08-11),

8. 10669235 - Indole derivatives and their use as protein kinase inhibitors (2020-06-02),

9. 10358445 - Respiratory formulations and compounds for use therein (2019-07-23),

10. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

11. 10266519 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2019-04-23),

12. 10238658 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2019-03-26),

13. 10144721 - P38 MAP kinase inhibitors (2018-12-04),

14. 10125100 - Kinase inhibitors (2018-11-13),

15. 10072034 - Kinase inhibitors (2018-09-11),

Company Overview

Respivert Limited, based in Buckinghamshire, specializes in the development of innovative kinase inhibitors with a focus on addressing fibrotic diseases and respiratory conditions. The company's core technologies include P38 MAP Kinase and Phosphoinositide 3-Kinase inhibitors, alongside research into indole derivatives and pyrazolyl-ureas. By leveraging its expertise in protein kinase inhibitors, Respivert aims to create effective therapeutic solutions that enhance patient outcomes in challenging medical areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

63 Patents

#3 in Buckinghamshire

#293 in United Kingdom

#11,643 in the World

Buckinghamshire, United Kingdom

Respivert Limited

Forward Citations = 642

52 inventors:

John King-Underwood (38 out of 39 patents)

Stuart Thomas Onions (37 out of 67 patents)

Kazuhiro Ito (27 out of 49 patents)

4. Peter John Murray (23 out of 38 patents)

5. Catherine Elisabeth Charron (21 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Respivert Limited. Retrieved from https://idiyas.com/company/respivert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…